Descripciones mejoradas de Syndetics:

Completely updated, The new Seventh Edition of Generic and Innovator Drugs: A Guide to FDA Approval Requirements provides indispensable and practical insights into the FDA approval process. You'll find comprehensive coverage of: Abbreviated new drug applications 505(b)(2) new drug applications Delaying approval of competing products FDA approval of biologic drugs No other book can cover the drug approval process as thoroughly, answering important questions like these: What is required to extend the patent of an FDA -approved product? When must a generic manufacturer notify the innovator manufacturer when submitting an ANDA or 505(b)(2) application? When does the FDA delay approvals because of patent claims, and when does it ignore patents? How can one challenge an FDA exclusivity decision? When can a manufacturer safely sell a drug without prior FDA approval? In what circumstances can a generic manufacturer obtain FDA permission to file an ANDA for a variant of an existing drug? When will the FDA waive or reduce prescription drug user fees? How can a company or an individual avoid debarment? What steps are necessary to comply with the FDA 's Fraud Policy? When and how can a drug company take advantage of FDA accelerated approval procedures? What are the labeling requirements for exporting approved drugs? How does the FDAAA of 2007 affect the drug and biologic approval requirements? Generic and Innovator Drugs: A Guide to FDA Approval Requirements provides step by step guidance of the approval process and expert interpretation of: the Hatch-Waxman Act (Drug Price Competition and Patent Restoration Act) the Medicare Prescription Drug, Improvement, and Modernization Act the Food and Drug Administration Modernization Act the FDA Export Reform and Enhancement Act the Food and Drug Administration Amendments Act of 2007 and more!

Tabla de contenidos provista por Syndetics

• Fda Approval Requirements
• Full New Drug Applications
• Abbreviated New Drug Applications And 505(B)(2) Applications
• Delaying Approval Of Competitive Products
• Public Availability Of Drug And Biologic Data
• Potential For Government Compensation Of Innovators
• The Orphan Drug Amendments
• Debarment And Civil Penalties
• Fda Fraud Policy
• Accelerated Approvals
• Export And Import Requirements
• Prescription Drug User Fees
• Fda Regulation Of Biologic Drugs